In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period

References

• Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8:751–62.
   PubMed Web of Science ®Google Scholar
• Abbott I, Cerqueira GM, Bhuiyan S, Peleg AY. Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev Anti Infect Ther. 2013;11:395–409.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents. 2008;32:106–19.
   PubMed Web of Science ®Google Scholar
• Vila J, Pachon J. Acinetobacter baumannii resistant to every thing, what should we do? Clin Microbiol Infect. 2011;17:955–6.
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:3471–84.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358:1271–81.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case–control studies. Crit Care. 2006;10:R48.
   PubMed Web of Science ®Google Scholar
• Nigro SJ, Post V, Hall RM. Aminoglycoside resistance in multiply antibiotic-resistant Acinetobacter baumannii belonging to global clone 2 from Australian hospitals. J Antimicrob Chemother. 2011;66:1504–9.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194–9.
   PubMed Web of Science ®Google Scholar
• Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963–71.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Table 2B-2. Zone Diameter and MIC Interpretive Standards for Acinetobacter spp. M02 and M07 In Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. M100-S21. Wayne, PA, USA: CLSI; 2011.
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Appendix A. Suggested test result verification and organism identification. In performance standards for antimicrobial susceptibility testing; Twenty-First Informational Supplement. M100-S21. Wayne, PA, USA: CLSI; 2011. p. 144–146.
   Google Scholar
• Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 2008;13:1–11.
   Google Scholar
• Perez F, Endimiani A, Ray AJ, Decker BK, Wallace CJ, Hujer KM, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother. 2010;65:1807–18.
   PubMed Web of Science ®Google Scholar
• Markelz AE, Mende K, Murray CK, Yu X, Zera WC, Hospenthal DR, et al. Carbapenem susceptibility testing errors using three automated systems, disk diffusion, Etest, and broth microdilution and carbapenem resistance genes in isolates of Acinetobacter baumannii–calcoaceticus complex. Antimicrob Agents Chemother. 2011;55:4707–11.
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Altouvas G, Pitiriga V, Tziraki M, Mamali V, et al. Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant Gram-negative pathogens. J Clin Microbiol. 2012;50:3747–50.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Annual Epidemiological Report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data. Stockholm, Sweden: ECDC; 2013.
   Google Scholar
• Falagas ME, Mourtzoukou EG, Polemis M, Vatopoulos AC, Greek System for Surveillance of Antimicrobial Resistance. Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalized patients in Greece and treatment implications. Clin Microbiol Infect. 2007;13:816–9.
   PubMed Web of Science ®Google Scholar
• Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother. 2006;50:3166–9.
   PubMed Web of Science ®Google Scholar
• Rodloff AC, Leclercq R, Debbia EA, Canton R, Oppenheim BA, Dowzicky MJ. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin Microbiol Infect. 2008;14:307–14.
   PubMed Web of Science ®Google Scholar
• Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007;59:772–4.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Prescribing information for tygacil (tigecycline); 2010. Available at www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf
   Google Scholar
• Food and Drug Administration (FDA). FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial tygacil (tigecycline) and approves new boxed warning; 2013. Available at www.fda.gov/Drugs/DrugSafety/ucm369580.htm
   Google Scholar
• Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother. 2008;62:45–55.
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. Available at http://www.eucast.org
   Google Scholar
• Bishburg E, Bishburg K. Minocycline-an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents. 2009;34:395–401.
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50:2946–50.
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:3022–4.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents. 2008;32:450–4.
   PubMed Web of Science ®Google Scholar
• Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case–control study. Crit Care Med. 2008;36:807–11.
   PubMed Web of Science ®Google Scholar
• Raoult D, Richet H. Nosocomial bacteremia: the most neglected causes of death in Europe? Clin Microbiol Infect. 2011;17:1123.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY. Antimicrobial Surveillance Program (1997–2002). Diagn Microbiol Infect Dis. 2004;50:59–69.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.
   PubMed Web of Science ®Google Scholar
• Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KL. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob Chemother. 2011;66:1625–30.
   PubMed Web of Science ®Google Scholar
• MMWR, CDC. Vital signs: central line-associated blood stream infections-United States, 2001, 2008, and 2009. MMWR, CDC, 2011;60:243–8.
   PubMedGoogle Scholar